| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Lupus Erythematosus, Systemic | 134 | 2022 | 756 | 16.610 |
Why?
|
| Genetic Predisposition to Disease | 35 | 2022 | 785 | 2.260 |
Why?
|
| Lupus Nephritis | 17 | 2022 | 193 | 2.200 |
Why?
|
| Vitamin D Deficiency | 13 | 2021 | 292 | 1.950 |
Why?
|
| Antibodies, Antinuclear | 19 | 2022 | 171 | 1.770 |
Why?
|
| Autoantibodies | 19 | 2022 | 434 | 1.480 |
Why?
|
| Polymorphism, Single Nucleotide | 34 | 2021 | 627 | 1.410 |
Why?
|
| Environmental Exposure | 4 | 2015 | 269 | 1.360 |
Why?
|
| Humans | 166 | 2022 | 68525 | 1.270 |
Why?
|
| Lupus Vasculitis, Central Nervous System | 5 | 2020 | 14 | 1.240 |
Why?
|
| Vitamin D | 15 | 2021 | 516 | 1.240 |
Why?
|
| Glucocorticoids | 7 | 2021 | 222 | 1.170 |
Why?
|
| Female | 112 | 2022 | 38015 | 1.110 |
Why?
|
| Adult | 78 | 2022 | 21375 | 1.080 |
Why?
|
| Alkanesulfonic Acids | 2 | 2015 | 54 | 0.980 |
Why?
|
| Immunosuppressive Agents | 9 | 2022 | 514 | 0.970 |
Why?
|
| Fluorocarbons | 2 | 2015 | 82 | 0.950 |
Why?
|
| Antibodies, Antiphospholipid | 4 | 2021 | 29 | 0.940 |
Why?
|
| Case-Control Studies | 27 | 2022 | 1548 | 0.930 |
Why?
|
| Male | 94 | 2022 | 37281 | 0.930 |
Why?
|
| Patient Compliance | 4 | 2015 | 402 | 0.920 |
Why?
|
| Autoimmunity | 5 | 2022 | 118 | 0.920 |
Why?
|
| Severity of Illness Index | 16 | 2022 | 1851 | 0.910 |
Why?
|
| Rheumatology | 5 | 2021 | 46 | 0.890 |
Why?
|
| Joint Diseases | 1 | 2022 | 37 | 0.890 |
Why?
|
| Fibromyalgia | 1 | 2022 | 29 | 0.880 |
Why?
|
| Quality of Life | 12 | 2022 | 1515 | 0.880 |
Why?
|
| Young Adult | 40 | 2022 | 5708 | 0.880 |
Why?
|
| Antirheumatic Agents | 4 | 2022 | 58 | 0.860 |
Why?
|
| Middle Aged | 64 | 2022 | 21119 | 0.850 |
Why?
|
| Mesenchymal Stem Cell Transplantation | 1 | 2022 | 63 | 0.820 |
Why?
|
| Autoimmune Diseases | 7 | 2018 | 186 | 0.800 |
Why?
|
| Videoconferencing | 1 | 2021 | 43 | 0.770 |
Why?
|
| Haplotypes | 20 | 2018 | 174 | 0.730 |
Why?
|
| Frailty | 4 | 2022 | 34 | 0.720 |
Why?
|
| Cohort Studies | 24 | 2021 | 2356 | 0.690 |
Why?
|
| Transportation of Patients | 2 | 2016 | 46 | 0.660 |
Why?
|
| Disease Progression | 13 | 2022 | 1037 | 0.650 |
Why?
|
| Patient Education as Topic | 1 | 2021 | 424 | 0.630 |
Why?
|
| Cholecalciferol | 2 | 2015 | 143 | 0.620 |
Why?
|
| Cost of Illness | 2 | 2016 | 204 | 0.610 |
Why?
|
| Health Services Accessibility | 3 | 2020 | 581 | 0.610 |
Why?
|
| Pandemics | 1 | 2021 | 346 | 0.600 |
Why?
|
| Gastrointestinal Diseases | 1 | 2018 | 107 | 0.600 |
Why?
|
| Heart Valve Diseases | 1 | 2017 | 123 | 0.570 |
Why?
|
| Models, Theoretical | 2 | 2021 | 384 | 0.550 |
Why?
|
| Risk Factors | 24 | 2021 | 5719 | 0.540 |
Why?
|
| Environmental Pollutants | 2 | 2015 | 180 | 0.540 |
Why?
|
| Endothelium | 1 | 2015 | 98 | 0.540 |
Why?
|
| Alleles | 15 | 2018 | 386 | 0.530 |
Why?
|
| Health Care Surveys | 1 | 2016 | 239 | 0.520 |
Why?
|
| Immunologic Factors | 2 | 2020 | 87 | 0.510 |
Why?
|
| Information Systems | 1 | 2014 | 45 | 0.500 |
Why?
|
| Interleukin-2 | 2 | 2014 | 133 | 0.500 |
Why?
|
| Caprylates | 1 | 2014 | 32 | 0.500 |
Why?
|
| Myositis | 1 | 2014 | 24 | 0.490 |
Why?
|
| South Carolina | 11 | 2020 | 2750 | 0.480 |
Why?
|
| Osteoporosis | 2 | 2018 | 88 | 0.470 |
Why?
|
| Immunoglobulins, Intravenous | 1 | 2014 | 52 | 0.470 |
Why?
|
| Myocarditis | 1 | 2014 | 49 | 0.470 |
Why?
|
| Biomarkers | 13 | 2022 | 1593 | 0.460 |
Why?
|
| Cyclophosphamide | 3 | 2020 | 129 | 0.460 |
Why?
|
| Bone and Bones | 2 | 2011 | 145 | 0.460 |
Why?
|
| Antimalarials | 4 | 2022 | 71 | 0.450 |
Why?
|
| Longitudinal Studies | 10 | 2021 | 1054 | 0.450 |
Why?
|
| Rheumatic Diseases | 4 | 2021 | 35 | 0.450 |
Why?
|
| CD4-Positive T-Lymphocytes | 1 | 2014 | 226 | 0.440 |
Why?
|
| Hydroxychloroquine | 3 | 2022 | 14 | 0.440 |
Why?
|
| Referral and Consultation | 1 | 2014 | 383 | 0.420 |
Why?
|
| Patient Selection | 2 | 2020 | 592 | 0.410 |
Why?
|
| Genome-Wide Association Study | 7 | 2018 | 240 | 0.410 |
Why?
|
| Genotype | 17 | 2021 | 785 | 0.410 |
Why?
|
| Logistic Models | 9 | 2019 | 1419 | 0.400 |
Why?
|
| Health Personnel | 1 | 2014 | 286 | 0.400 |
Why?
|
| Cross-Sectional Studies | 11 | 2022 | 2264 | 0.400 |
Why?
|
| Bone Diseases | 1 | 2010 | 20 | 0.390 |
Why?
|
| Adolescent | 20 | 2022 | 8903 | 0.380 |
Why?
|
| Pleural Diseases | 1 | 2010 | 20 | 0.380 |
Why?
|
| Health Behavior | 2 | 2016 | 458 | 0.380 |
Why?
|
| Exercise | 2 | 2013 | 657 | 0.370 |
Why?
|
| Clinical Trials as Topic | 1 | 2014 | 848 | 0.370 |
Why?
|
| Metabolic Syndrome | 3 | 2021 | 191 | 0.370 |
Why?
|
| Research Design | 1 | 2014 | 729 | 0.360 |
Why?
|
| Peroxidase | 2 | 2007 | 40 | 0.360 |
Why?
|
| Interleukin-10 | 3 | 2022 | 144 | 0.360 |
Why?
|
| Microbiota | 2 | 2022 | 79 | 0.360 |
Why?
|
| STAT1 Transcription Factor | 4 | 2018 | 35 | 0.350 |
Why?
|
| Inflammation | 5 | 2022 | 1030 | 0.340 |
Why?
|
| NADPH Oxidases | 2 | 2021 | 80 | 0.340 |
Why?
|
| Aged | 19 | 2022 | 14842 | 0.340 |
Why?
|
| Fluorescent Antibody Technique, Indirect | 3 | 2022 | 95 | 0.340 |
Why?
|
| Interferon Regulatory Factors | 3 | 2014 | 24 | 0.340 |
Why?
|
| Arthritis, Rheumatoid | 3 | 2018 | 155 | 0.340 |
Why?
|
| Communicable Disease Control | 1 | 2009 | 26 | 0.340 |
Why?
|
| Lung Diseases | 1 | 2010 | 175 | 0.330 |
Why?
|
| Europe | 9 | 2021 | 195 | 0.330 |
Why?
|
| Communicable Diseases | 1 | 2009 | 49 | 0.330 |
Why?
|
| beta 2-Glycoprotein I | 3 | 2021 | 10 | 0.330 |
Why?
|
| Adaptation, Psychological | 1 | 2011 | 447 | 0.320 |
Why?
|
| Headache | 2 | 2021 | 68 | 0.320 |
Why?
|
| Prospective Studies | 13 | 2022 | 3702 | 0.310 |
Why?
|
| Antibodies, Monoclonal, Humanized | 2 | 2020 | 151 | 0.310 |
Why?
|
| International Cooperation | 5 | 2019 | 88 | 0.290 |
Why?
|
| DNA | 7 | 2022 | 597 | 0.280 |
Why?
|
| Family | 3 | 2019 | 293 | 0.280 |
Why?
|
| Glomerulonephritis | 1 | 2006 | 77 | 0.280 |
Why?
|
| Genetic Loci | 5 | 2013 | 59 | 0.280 |
Why?
|
| Follow-Up Studies | 11 | 2021 | 3256 | 0.270 |
Why?
|
| Gene Expression Regulation | 7 | 2019 | 1293 | 0.270 |
Why?
|
| Surveys and Questionnaires | 5 | 2022 | 2798 | 0.260 |
Why?
|
| Multivariate Analysis | 5 | 2019 | 1046 | 0.260 |
Why?
|
| Immunoglobulin A | 2 | 2022 | 79 | 0.260 |
Why?
|
| Internationality | 5 | 2019 | 74 | 0.260 |
Why?
|
| Health Status | 3 | 2018 | 429 | 0.260 |
Why?
|
| STAT4 Transcription Factor | 2 | 2018 | 12 | 0.250 |
Why?
|
| Child | 12 | 2022 | 6400 | 0.250 |
Why?
|
| Atherosclerosis | 2 | 2020 | 204 | 0.250 |
Why?
|
| Immunoconjugates | 1 | 2014 | 26 | 0.250 |
Why?
|
| Kidney | 5 | 2022 | 945 | 0.250 |
Why?
|
| Prevalence | 8 | 2020 | 1609 | 0.250 |
Why?
|
| B-Lymphocyte Subsets | 2 | 2022 | 25 | 0.240 |
Why?
|
| Lipoproteins, HDL | 3 | 2014 | 113 | 0.240 |
Why?
|
| Polymorphism, Genetic | 2 | 2018 | 301 | 0.240 |
Why?
|
| Terminology as Topic | 2 | 2018 | 141 | 0.240 |
Why?
|
| Healthcare Disparities | 2 | 2020 | 378 | 0.240 |
Why?
|
| Consensus | 3 | 2019 | 211 | 0.230 |
Why?
|
| Annexin A5 | 1 | 2013 | 16 | 0.230 |
Why?
|
| Carrier Proteins | 3 | 2016 | 597 | 0.230 |
Why?
|
| Risk Assessment | 5 | 2019 | 2004 | 0.230 |
Why?
|
| Leukocytes, Mononuclear | 3 | 2022 | 124 | 0.230 |
Why?
|
| Promoter Regions, Genetic | 4 | 2014 | 614 | 0.230 |
Why?
|
| Kidney Diseases | 2 | 2021 | 307 | 0.230 |
Why?
|
| Adaptor Proteins, Signal Transducing | 4 | 2018 | 214 | 0.220 |
Why?
|
| United States | 15 | 2021 | 7335 | 0.220 |
Why?
|
| Apolipoproteins | 2 | 2014 | 51 | 0.220 |
Why?
|
| Gastrointestinal Microbiome | 2 | 2022 | 121 | 0.220 |
Why?
|
| Arthralgia | 1 | 2022 | 30 | 0.220 |
Why?
|
| Transforming Growth Factor beta | 2 | 2022 | 384 | 0.220 |
Why?
|
| Proteinuria | 3 | 2022 | 136 | 0.220 |
Why?
|
| Umbilical Cord | 1 | 2022 | 19 | 0.220 |
Why?
|
| Residence Characteristics | 2 | 2015 | 252 | 0.220 |
Why?
|
| Socioeconomic Factors | 2 | 2016 | 955 | 0.220 |
Why?
|
| Genetic Diseases, X-Linked | 1 | 2022 | 24 | 0.220 |
Why?
|
| Retinal Diseases | 1 | 2022 | 40 | 0.220 |
Why?
|
| Up-Regulation | 3 | 2022 | 682 | 0.210 |
Why?
|
| Scleroderma, Systemic | 1 | 2006 | 446 | 0.210 |
Why?
|
| Dietary Supplements | 3 | 2015 | 331 | 0.210 |
Why?
|
| Causality | 1 | 2022 | 81 | 0.210 |
Why?
|
| DNA-Binding Proteins | 4 | 2014 | 700 | 0.210 |
Why?
|
| Symptom Flare Up | 1 | 2021 | 20 | 0.210 |
Why?
|
| Macrophages | 2 | 2021 | 647 | 0.210 |
Why?
|
| Kidney Failure, Chronic | 2 | 2016 | 365 | 0.210 |
Why?
|
| E2F Transcription Factors | 1 | 2022 | 48 | 0.210 |
Why?
|
| Quantitative Trait Loci | 2 | 2018 | 35 | 0.210 |
Why?
|
| Patient Reported Outcome Measures | 1 | 2022 | 114 | 0.200 |
Why?
|
| Video Games | 2 | 2012 | 39 | 0.200 |
Why?
|
| Proportional Hazards Models | 7 | 2019 | 791 | 0.200 |
Why?
|
| Arteriovenous Fistula | 1 | 2021 | 25 | 0.200 |
Why?
|
| Staphylococcus aureus | 1 | 2022 | 175 | 0.200 |
Why?
|
| Sex Factors | 6 | 2021 | 1265 | 0.200 |
Why?
|
| Membrane Proteins | 2 | 2018 | 617 | 0.200 |
Why?
|
| Linkage Disequilibrium | 7 | 2016 | 91 | 0.190 |
Why?
|
| Rituximab | 1 | 2020 | 61 | 0.190 |
Why?
|
| Lipopolysaccharides | 2 | 2019 | 455 | 0.190 |
Why?
|
| Decision Support Techniques | 2 | 2019 | 191 | 0.190 |
Why?
|
| Drug Costs | 1 | 2020 | 87 | 0.190 |
Why?
|
| Bone Density | 3 | 2011 | 159 | 0.190 |
Why?
|
| Incidence | 6 | 2022 | 1582 | 0.180 |
Why?
|
| Societies, Medical | 2 | 2019 | 403 | 0.180 |
Why?
|
| Exercise Therapy | 2 | 2012 | 183 | 0.180 |
Why?
|
| Cranial Nerve Diseases | 1 | 2019 | 14 | 0.180 |
Why?
|
| Receptors, Urokinase Plasminogen Activator | 1 | 2019 | 14 | 0.180 |
Why?
|
| Research Personnel | 2 | 2018 | 83 | 0.180 |
Why?
|
| Treatment Outcome | 8 | 2021 | 7028 | 0.180 |
Why?
|
| Peripheral Nervous System Diseases | 1 | 2019 | 37 | 0.180 |
Why?
|
| Sjogren's Syndrome | 2 | 2017 | 18 | 0.180 |
Why?
|
| Insulin Resistance | 1 | 2021 | 241 | 0.180 |
Why?
|
| Contraceptives, Oral, Hormonal | 1 | 2019 | 8 | 0.180 |
Why?
|
| Occludin | 1 | 2019 | 7 | 0.180 |
Why?
|
| Contraceptives, Oral, Combined | 1 | 2019 | 6 | 0.180 |
Why?
|
| Genetic Association Studies | 6 | 2018 | 103 | 0.180 |
Why?
|
| Psychotic Disorders | 2 | 2019 | 157 | 0.180 |
Why?
|
| Antigens, Viral | 1 | 2019 | 35 | 0.180 |
Why?
|
| Herpesviridae Infections | 1 | 2019 | 23 | 0.180 |
Why?
|
| Bacterial Translocation | 1 | 2019 | 27 | 0.180 |
Why?
|
| Herpesvirus 4, Human | 1 | 2019 | 30 | 0.180 |
Why?
|
| Serologic Tests | 1 | 2019 | 46 | 0.170 |
Why?
|
| Pain | 1 | 2022 | 472 | 0.170 |
Why?
|
| Osteopontin | 1 | 2019 | 28 | 0.170 |
Why?
|
| Minority Groups | 1 | 2020 | 196 | 0.170 |
Why?
|
| Major Histocompatibility Complex | 1 | 2018 | 34 | 0.170 |
Why?
|
| Antibodies, Viral | 1 | 2019 | 110 | 0.160 |
Why?
|
| Foundations | 1 | 2018 | 17 | 0.160 |
Why?
|
| Models, Statistical | 3 | 2020 | 446 | 0.160 |
Why?
|
| Progesterone | 1 | 2019 | 115 | 0.160 |
Why?
|
| Age Factors | 5 | 2019 | 1860 | 0.160 |
Why?
|
| Vitamin D3 24-Hydroxylase | 2 | 2016 | 24 | 0.160 |
Why?
|
| Hospitalization | 2 | 2022 | 977 | 0.160 |
Why?
|
| Sensitivity and Specificity | 6 | 2021 | 1753 | 0.160 |
Why?
|
| Nucleosomes | 1 | 2017 | 25 | 0.160 |
Why?
|
| Myxovirus Resistance Proteins | 2 | 2015 | 4 | 0.160 |
Why?
|
| Delivery of Health Care | 2 | 2020 | 445 | 0.160 |
Why?
|
| Genetic Load | 1 | 2017 | 4 | 0.160 |
Why?
|
| Antigens | 2 | 2015 | 90 | 0.160 |
Why?
|
| Mitral Valve Stenosis | 1 | 2017 | 15 | 0.150 |
Why?
|
| Patient Participation | 2 | 2020 | 145 | 0.150 |
Why?
|
| Early Diagnosis | 1 | 2018 | 122 | 0.150 |
Why?
|
| Gastrointestinal Tract | 1 | 2018 | 62 | 0.150 |
Why?
|
| Tricuspid Valve Insufficiency | 1 | 2017 | 25 | 0.150 |
Why?
|
| Cerebrovascular Disorders | 1 | 2018 | 182 | 0.150 |
Why?
|
| Osteoarthritis | 1 | 2018 | 73 | 0.150 |
Why?
|
| Gene-Environment Interaction | 2 | 2014 | 31 | 0.150 |
Why?
|
| Premature Birth | 1 | 2019 | 148 | 0.150 |
Why?
|
| Aortic Valve Insufficiency | 1 | 2017 | 47 | 0.150 |
Why?
|
| North America | 4 | 2019 | 111 | 0.150 |
Why?
|
| Immunity, Innate | 2 | 2010 | 156 | 0.150 |
Why?
|
| Aspirin | 1 | 2018 | 295 | 0.150 |
Why?
|
| HLA Antigens | 1 | 2017 | 82 | 0.150 |
Why?
|
| Jurkat Cells | 2 | 2014 | 59 | 0.150 |
Why?
|
| Cytoskeletal Proteins | 2 | 2015 | 108 | 0.150 |
Why?
|
| Interviews as Topic | 2 | 2015 | 392 | 0.150 |
Why?
|
| Epigenesis, Genetic | 1 | 2018 | 163 | 0.150 |
Why?
|
| Smoking | 4 | 2021 | 1449 | 0.150 |
Why?
|
| Mitral Valve Insufficiency | 1 | 2017 | 99 | 0.150 |
Why?
|
| Self Report | 2 | 2022 | 370 | 0.150 |
Why?
|
| Pre-Eclampsia | 1 | 2018 | 202 | 0.140 |
Why?
|
| Drug Prescriptions | 1 | 2018 | 135 | 0.140 |
Why?
|
| Sex Chromosome Disorders of Sex Development | 1 | 2016 | 3 | 0.140 |
Why?
|
| Decision Making | 1 | 2020 | 410 | 0.140 |
Why?
|
| Neoplasms | 2 | 2021 | 1660 | 0.140 |
Why?
|
| Liver Cirrhosis, Biliary | 1 | 2016 | 9 | 0.140 |
Why?
|
| Platelet Aggregation Inhibitors | 1 | 2018 | 373 | 0.140 |
Why?
|
| Biopsy | 4 | 2021 | 539 | 0.140 |
Why?
|
| Nicotinamide-Nucleotide Adenylyltransferase | 1 | 2016 | 5 | 0.140 |
Why?
|
| Lymphoma, Non-Hodgkin | 2 | 2013 | 36 | 0.140 |
Why?
|
| Disease Management | 1 | 2018 | 248 | 0.140 |
Why?
|
| Asia | 4 | 2019 | 59 | 0.140 |
Why?
|
| Artificial Intelligence | 1 | 2017 | 159 | 0.140 |
Why?
|
| Heart Valve Prosthesis | 1 | 2017 | 222 | 0.140 |
Why?
|
| Genetic Linkage | 2 | 2018 | 90 | 0.140 |
Why?
|
| Pregnancy Complications | 1 | 2018 | 286 | 0.140 |
Why?
|
| Receptors, Calcitriol | 3 | 2016 | 49 | 0.130 |
Why?
|
| Mobility Limitation | 1 | 2015 | 27 | 0.130 |
Why?
|
| Glomerular Filtration Rate | 1 | 2016 | 274 | 0.130 |
Why?
|
| Aortic Valve Stenosis | 1 | 2017 | 177 | 0.130 |
Why?
|
| Inflammation Mediators | 1 | 2017 | 244 | 0.130 |
Why?
|
| Leptin | 1 | 2015 | 80 | 0.130 |
Why?
|
| Body Mass Index | 3 | 2014 | 866 | 0.130 |
Why?
|
| CD3 Complex | 1 | 2015 | 35 | 0.130 |
Why?
|
| Registries | 3 | 2019 | 730 | 0.130 |
Why?
|
| Vascular Diseases | 1 | 2015 | 94 | 0.130 |
Why?
|
| Odds Ratio | 1 | 2017 | 880 | 0.130 |
Why?
|
| Proto-Oncogene Protein c-ets-1 | 1 | 2015 | 65 | 0.130 |
Why?
|
| Dose-Response Relationship, Drug | 4 | 2018 | 1745 | 0.130 |
Why?
|
| beta Karyopherins | 1 | 2014 | 4 | 0.130 |
Why?
|
| Lupus Coagulation Inhibitor | 3 | 2019 | 15 | 0.130 |
Why?
|
| Phytohemagglutinins | 1 | 2014 | 16 | 0.130 |
Why?
|
| Primary Health Care | 1 | 2020 | 702 | 0.130 |
Why?
|
| Complement C1q | 1 | 2014 | 18 | 0.130 |
Why?
|
| Interferon-alpha | 2 | 2011 | 46 | 0.130 |
Why?
|
| Diet Surveys | 1 | 2014 | 24 | 0.130 |
Why?
|
| Tandem Mass Spectrometry | 1 | 2015 | 139 | 0.130 |
Why?
|
| Time Factors | 5 | 2020 | 4655 | 0.130 |
Why?
|
| Time | 1 | 2014 | 57 | 0.120 |
Why?
|
| PPAR alpha | 1 | 2014 | 31 | 0.120 |
Why?
|
| Administration, Oral | 1 | 2015 | 411 | 0.120 |
Why?
|
| Physicians | 1 | 2018 | 324 | 0.120 |
Why?
|
| Receptors, Complement 3d | 1 | 2014 | 45 | 0.120 |
Why?
|
| Tetradecanoylphorbol Acetate | 1 | 2014 | 138 | 0.120 |
Why?
|
| Echocardiography | 1 | 2017 | 515 | 0.120 |
Why?
|
| Prognosis | 5 | 2019 | 2093 | 0.120 |
Why?
|
| Chromatography, High Pressure Liquid | 1 | 2015 | 381 | 0.120 |
Why?
|
| Academic Medical Centers | 2 | 2015 | 281 | 0.120 |
Why?
|
| Principal Component Analysis | 1 | 2014 | 55 | 0.120 |
Why?
|
| Adrenal Cortex Hormones | 1 | 2015 | 186 | 0.120 |
Why?
|
| Double-Blind Method | 4 | 2018 | 1737 | 0.120 |
Why?
|
| Mood Disorders | 1 | 2015 | 132 | 0.120 |
Why?
|
| ets-Domain Protein Elk-1 | 1 | 2013 | 14 | 0.120 |
Why?
|
| Tumor Necrosis Factor-alpha | 2 | 2019 | 626 | 0.120 |
Why?
|
| Immunity | 1 | 2014 | 67 | 0.120 |
Why?
|
| Fatigue | 2 | 2012 | 132 | 0.120 |
Why?
|
| Self Care | 1 | 2016 | 252 | 0.120 |
Why?
|
| Reproducibility of Results | 4 | 2021 | 2077 | 0.120 |
Why?
|
| OX40 Ligand | 1 | 2013 | 7 | 0.120 |
Why?
|
| Pilot Projects | 2 | 2015 | 1341 | 0.120 |
Why?
|
| Electronic Health Records | 1 | 2017 | 374 | 0.120 |
Why?
|
| src-Family Kinases | 1 | 2014 | 91 | 0.120 |
Why?
|
| Qualitative Research | 1 | 2015 | 368 | 0.120 |
Why?
|
| Computers | 1 | 2013 | 63 | 0.120 |
Why?
|
| MicroRNAs | 2 | 2022 | 447 | 0.120 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 2 | 2012 | 216 | 0.110 |
Why?
|
| Toll-Like Receptor 7 | 1 | 2013 | 17 | 0.110 |
Why?
|
| Hodgkin Disease | 1 | 2013 | 27 | 0.110 |
Why?
|
| Telomere | 1 | 2013 | 59 | 0.110 |
Why?
|
| Antibody Specificity | 1 | 2012 | 98 | 0.110 |
Why?
|
| Rural Population | 1 | 2016 | 397 | 0.110 |
Why?
|
| International Agencies | 1 | 2012 | 17 | 0.110 |
Why?
|
| Personnel Turnover | 1 | 2012 | 14 | 0.110 |
Why?
|
| Delphi Technique | 3 | 2019 | 62 | 0.110 |
Why?
|
| Egg Proteins | 1 | 2012 | 15 | 0.110 |
Why?
|
| Phenotype | 5 | 2014 | 946 | 0.110 |
Why?
|
| Ikaros Transcription Factor | 1 | 2012 | 26 | 0.110 |
Why?
|
| Personnel Selection | 1 | 2012 | 37 | 0.110 |
Why?
|
| TNF Receptor-Associated Factor 6 | 1 | 2012 | 14 | 0.110 |
Why?
|
| Molecular Motor Proteins | 1 | 2011 | 14 | 0.110 |
Why?
|
| Ubiquitin-Conjugating Enzymes | 1 | 2012 | 22 | 0.100 |
Why?
|
| Immune System Diseases | 1 | 2011 | 12 | 0.100 |
Why?
|
| Transcription, Genetic | 1 | 2014 | 562 | 0.100 |
Why?
|
| Feces | 2 | 2022 | 88 | 0.100 |
Why?
|
| Complement System Proteins | 3 | 2019 | 135 | 0.100 |
Why?
|
| Myosin Heavy Chains | 1 | 2011 | 49 | 0.100 |
Why?
|
| Mass Screening | 1 | 2018 | 837 | 0.100 |
Why?
|
| Caregivers | 1 | 2015 | 365 | 0.100 |
Why?
|
| Remission Induction | 2 | 2022 | 111 | 0.100 |
Why?
|
| Angiotensin-Converting Enzyme Inhibitors | 1 | 2012 | 201 | 0.100 |
Why?
|
| Faculty, Medical | 1 | 2012 | 110 | 0.100 |
Why?
|
| Predictive Value of Tests | 3 | 2021 | 1465 | 0.100 |
Why?
|
| Cell Survival | 1 | 2014 | 901 | 0.100 |
Why?
|
| Complement Factor H | 1 | 2011 | 21 | 0.100 |
Why?
|
| Protein Phosphatase 2 | 1 | 2011 | 67 | 0.100 |
Why?
|
| Exodeoxyribonucleases | 1 | 2011 | 8 | 0.100 |
Why?
|
| Pyruvate Dehydrogenase Complex | 1 | 2010 | 9 | 0.100 |
Why?
|
| Chromosomes, Human, Pair 11 | 1 | 2010 | 32 | 0.100 |
Why?
|
| Cell Adhesion Molecules | 1 | 2012 | 199 | 0.100 |
Why?
|
| Osteonecrosis | 1 | 2010 | 20 | 0.100 |
Why?
|
| Drug Therapy, Combination | 2 | 2020 | 648 | 0.100 |
Why?
|
| Osteoporotic Fractures | 1 | 2010 | 9 | 0.100 |
Why?
|
| Microsatellite Repeats | 1 | 2010 | 40 | 0.100 |
Why?
|
| Permeability | 2 | 2022 | 131 | 0.100 |
Why?
|
| Bronchial Diseases | 1 | 2010 | 9 | 0.100 |
Why?
|
| Introns | 3 | 2018 | 68 | 0.100 |
Why?
|
| Antigens, Neoplasm | 1 | 2011 | 132 | 0.100 |
Why?
|
| Dendritic Cells | 2 | 2010 | 201 | 0.100 |
Why?
|
| Animals | 7 | 2022 | 20877 | 0.100 |
Why?
|
| Diagnosis, Differential | 2 | 2021 | 1139 | 0.090 |
Why?
|
| Nervous System Diseases | 1 | 2011 | 142 | 0.090 |
Why?
|
| Mice | 5 | 2022 | 8472 | 0.090 |
Why?
|
| Age of Onset | 3 | 2017 | 188 | 0.090 |
Why?
|
| Kaplan-Meier Estimate | 3 | 2019 | 536 | 0.090 |
Why?
|
| Immunoglobulin G | 2 | 2022 | 481 | 0.090 |
Why?
|
| Proto-Oncogene Protein c-fli-1 | 1 | 2010 | 106 | 0.090 |
Why?
|
| Adaptive Immunity | 1 | 2010 | 37 | 0.090 |
Why?
|
| Hyaluronan Receptors | 1 | 2010 | 142 | 0.090 |
Why?
|
| Bayes Theorem | 3 | 2017 | 303 | 0.090 |
Why?
|
| Anti-Inflammatory Agents | 1 | 2011 | 234 | 0.090 |
Why?
|
| Respiratory Tract Infections | 1 | 2010 | 91 | 0.090 |
Why?
|
| Phosphoproteins | 1 | 2011 | 202 | 0.090 |
Why?
|
| Models, Economic | 2 | 2020 | 69 | 0.090 |
Why?
|
| Osteoporosis, Postmenopausal | 1 | 2009 | 20 | 0.090 |
Why?
|
| Nuclear Proteins | 1 | 2011 | 271 | 0.090 |
Why?
|
| Aging | 1 | 2015 | 911 | 0.080 |
Why?
|
| Hip Joint | 1 | 2009 | 64 | 0.080 |
Why?
|
| Mice, Inbred C57BL | 3 | 2022 | 2790 | 0.080 |
Why?
|
| Antibodies, Monoclonal | 1 | 2011 | 510 | 0.080 |
Why?
|
| Anemia, Hemolytic | 1 | 2008 | 37 | 0.080 |
Why?
|
| Motivation | 1 | 2012 | 561 | 0.080 |
Why?
|
| Global Health | 2 | 2021 | 135 | 0.080 |
Why?
|
| Immune Tolerance | 1 | 2008 | 114 | 0.080 |
Why?
|
| Epilepsy | 1 | 2012 | 336 | 0.080 |
Why?
|
| Gene Frequency | 3 | 2013 | 207 | 0.080 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 2 | 2019 | 507 | 0.080 |
Why?
|
| Comorbidity | 3 | 2020 | 1425 | 0.080 |
Why?
|
| Biomarkers, Tumor | 1 | 2011 | 508 | 0.080 |
Why?
|
| Regression Analysis | 2 | 2021 | 737 | 0.070 |
Why?
|
| Rheumatoid Factor | 1 | 2006 | 21 | 0.070 |
Why?
|
| Immunoglobulin Isotypes | 1 | 2006 | 28 | 0.070 |
Why?
|
| Epidemiologic Methods | 3 | 2011 | 83 | 0.070 |
Why?
|
| Antimicrobial Cationic Peptides | 1 | 2006 | 21 | 0.070 |
Why?
|
| Toll-Like Receptors | 1 | 2006 | 56 | 0.070 |
Why?
|
| Mental Disorders | 1 | 2011 | 659 | 0.070 |
Why?
|
| Risk | 2 | 2020 | 563 | 0.070 |
Why?
|
| Lymphocytes | 2 | 2019 | 228 | 0.070 |
Why?
|
| Obesity | 1 | 2013 | 1074 | 0.070 |
Why?
|
| Calcitriol | 1 | 2006 | 106 | 0.070 |
Why?
|
| Algorithms | 3 | 2018 | 1194 | 0.070 |
Why?
|
| Immunophenotyping | 2 | 2019 | 110 | 0.070 |
Why?
|
| Renal Insufficiency | 1 | 2006 | 121 | 0.060 |
Why?
|
| Monocytes | 1 | 2006 | 210 | 0.060 |
Why?
|
| Mycobacterium tuberculosis | 1 | 2006 | 103 | 0.060 |
Why?
|
| Abatacept | 1 | 2014 | 17 | 0.060 |
Why?
|
| Seasons | 1 | 2005 | 129 | 0.060 |
Why?
|
| Practice Guidelines as Topic | 1 | 2010 | 772 | 0.060 |
Why?
|
| Health Status Disparities | 1 | 2008 | 326 | 0.060 |
Why?
|
| Flow Cytometry | 2 | 2019 | 489 | 0.060 |
Why?
|
| Antibodies, Anti-Idiotypic | 2 | 2015 | 43 | 0.060 |
Why?
|
| HEK293 Cells | 2 | 2016 | 326 | 0.060 |
Why?
|
| Pedigree | 2 | 2016 | 159 | 0.060 |
Why?
|
| Fluorescent Antibody Technique | 2 | 2014 | 282 | 0.060 |
Why?
|
| Indians, North American | 2 | 2014 | 64 | 0.060 |
Why?
|
| Apolipoprotein L1 | 2 | 2014 | 16 | 0.060 |
Why?
|
| Pregnancy | 2 | 2019 | 2331 | 0.060 |
Why?
|
| Chloroquine | 1 | 2022 | 21 | 0.060 |
Why?
|
| Cardiovascular Diseases | 1 | 2010 | 938 | 0.060 |
Why?
|
| Reference Values | 2 | 2019 | 579 | 0.060 |
Why?
|
| Ultraviolet Rays | 2 | 2014 | 130 | 0.050 |
Why?
|
| Peptidoglycan | 1 | 2022 | 14 | 0.050 |
Why?
|
| Cell Wall | 1 | 2022 | 21 | 0.050 |
Why?
|
| Antigens, Nuclear | 1 | 2022 | 24 | 0.050 |
Why?
|
| Kidney Function Tests | 1 | 2022 | 114 | 0.050 |
Why?
|
| Acetyltransferases | 1 | 2022 | 49 | 0.050 |
Why?
|
| Spermine | 1 | 2022 | 49 | 0.050 |
Why?
|
| Chromosome Mapping | 2 | 2013 | 188 | 0.050 |
Why?
|
| Ribosomal Proteins | 2 | 2012 | 18 | 0.050 |
Why?
|
| Homozygote | 1 | 2022 | 119 | 0.050 |
Why?
|
| Epigenomics | 1 | 2022 | 29 | 0.050 |
Why?
|
| Prednisone | 1 | 2022 | 104 | 0.050 |
Why?
|
| Mice, Inbred MRL lpr | 1 | 2022 | 118 | 0.050 |
Why?
|
| 25-Hydroxyvitamin D3 1-alpha-Hydroxylase | 2 | 2016 | 21 | 0.050 |
Why?
|
| Genetic Markers | 2 | 2012 | 144 | 0.050 |
Why?
|
| Receptors, Antigen, B-Cell | 1 | 2022 | 89 | 0.050 |
Why?
|
| Observational Studies as Topic | 1 | 2021 | 39 | 0.050 |
Why?
|
| Gene Knock-In Techniques | 1 | 2021 | 35 | 0.050 |
Why?
|
| Immunoglobulin M | 1 | 2022 | 172 | 0.050 |
Why?
|
| Africa | 1 | 2021 | 41 | 0.050 |
Why?
|
| Hematoma | 1 | 2021 | 47 | 0.050 |
Why?
|
| Protein Binding | 2 | 2015 | 1027 | 0.050 |
Why?
|
| NF-kappa B | 2 | 2013 | 432 | 0.050 |
Why?
|
| Models, Biological | 1 | 2005 | 981 | 0.050 |
Why?
|
| Lymphocyte Activation | 2 | 2014 | 397 | 0.050 |
Why?
|
| RNA-Binding Proteins | 2 | 2015 | 215 | 0.050 |
Why?
|
| Disease Models, Animal | 1 | 2008 | 2550 | 0.050 |
Why?
|
| Bacteria | 1 | 2022 | 193 | 0.050 |
Why?
|
| Multilevel Analysis | 1 | 2020 | 7 | 0.050 |
Why?
|
| Mononeuropathies | 1 | 2019 | 1 | 0.050 |
Why?
|
| North Carolina | 1 | 2020 | 224 | 0.050 |
Why?
|
| Transition to Adult Care | 1 | 2020 | 18 | 0.050 |
Why?
|
| Florida | 1 | 2020 | 221 | 0.050 |
Why?
|
| B-Lymphocytes | 2 | 2012 | 329 | 0.050 |
Why?
|
| Contraindications, Drug | 1 | 2019 | 1 | 0.040 |
Why?
|
| History, 21st Century | 1 | 2020 | 126 | 0.040 |
Why?
|
| Tight Junctions | 1 | 2019 | 25 | 0.040 |
Why?
|
| Migraine with Aura | 1 | 2019 | 6 | 0.040 |
Why?
|
| Caco-2 Cells | 1 | 2019 | 37 | 0.040 |
Why?
|
| Molecular Sequence Annotation | 1 | 2019 | 14 | 0.040 |
Why?
|
| Antiphospholipid Syndrome | 1 | 2019 | 25 | 0.040 |
Why?
|
| Infant, Newborn | 2 | 2020 | 2453 | 0.040 |
Why?
|
| Retrospective Studies | 3 | 2018 | 7264 | 0.040 |
Why?
|
| Single-Cell Analysis | 1 | 2019 | 35 | 0.040 |
Why?
|
| Interferons | 1 | 2019 | 36 | 0.040 |
Why?
|
| T-Lymphocytes | 2 | 2015 | 595 | 0.040 |
Why?
|
| Antibodies, Anticardiolipin | 1 | 2019 | 15 | 0.040 |
Why?
|
| Lymphopenia | 1 | 2018 | 12 | 0.040 |
Why?
|
| Leukocytes | 1 | 2019 | 99 | 0.040 |
Why?
|
| Complement C4 | 1 | 2018 | 15 | 0.040 |
Why?
|
| Mitosis | 1 | 2019 | 76 | 0.040 |
Why?
|
| Patient Outcome Assessment | 1 | 2019 | 42 | 0.040 |
Why?
|
| Rheumatologists | 1 | 2018 | 14 | 0.040 |
Why?
|
| Drug Utilization | 1 | 2019 | 119 | 0.040 |
Why?
|
| Core Binding Factor Alpha 3 Subunit | 1 | 2018 | 5 | 0.040 |
Why?
|
| Infant | 2 | 2020 | 2891 | 0.040 |
Why?
|
| Enhancer of Zeste Homolog 2 Protein | 1 | 2018 | 13 | 0.040 |
Why?
|
| Myeloid Cells | 1 | 2019 | 57 | 0.040 |
Why?
|
| Cluster Analysis | 1 | 2019 | 218 | 0.040 |
Why?
|
| Health Services Research | 1 | 2020 | 209 | 0.040 |
Why?
|
| Cost-Benefit Analysis | 1 | 2020 | 503 | 0.040 |
Why?
|
| Child, Preschool | 2 | 2020 | 3185 | 0.040 |
Why?
|
| Educational Status | 1 | 2019 | 273 | 0.040 |
Why?
|
| Complement C3 | 1 | 2018 | 101 | 0.040 |
Why?
|
| Computer Simulation | 1 | 2022 | 705 | 0.040 |
Why?
|
| Multicenter Studies as Topic | 1 | 2018 | 186 | 0.040 |
Why?
|
| Intestinal Mucosa | 1 | 2019 | 219 | 0.040 |
Why?
|
| Ambulatory Care | 1 | 2020 | 339 | 0.040 |
Why?
|
| Medicare | 1 | 2020 | 316 | 0.040 |
Why?
|
| Medicaid | 1 | 2020 | 301 | 0.040 |
Why?
|
| Models, Genetic | 1 | 2018 | 161 | 0.040 |
Why?
|
| Thrombocytopenia | 1 | 2018 | 122 | 0.040 |
Why?
|
| Unified Medical Language System | 1 | 2017 | 6 | 0.040 |
Why?
|
| Morbidity | 1 | 2018 | 130 | 0.040 |
Why?
|
| Computational Biology | 1 | 2019 | 190 | 0.040 |
Why?
|
| Transcriptome | 1 | 2019 | 164 | 0.040 |
Why?
|
| Mutagenesis, Insertional | 1 | 2017 | 24 | 0.040 |
Why?
|
| Multifactorial Inheritance | 1 | 2017 | 10 | 0.040 |
Why?
|
| Gene Expression | 2 | 2010 | 770 | 0.040 |
Why?
|
| Datasets as Topic | 1 | 2017 | 52 | 0.040 |
Why?
|
| RNA, Messenger | 2 | 2016 | 1663 | 0.040 |
Why?
|
| International Classification of Diseases | 1 | 2017 | 85 | 0.040 |
Why?
|
| Sequence Deletion | 1 | 2017 | 89 | 0.040 |
Why?
|
| Linear Models | 1 | 2019 | 521 | 0.040 |
Why?
|
| Gene Expression Profiling | 1 | 2019 | 498 | 0.040 |
Why?
|
| Binding Sites | 1 | 2018 | 631 | 0.040 |
Why?
|
| Epithelial Cells | 1 | 2019 | 431 | 0.040 |
Why?
|
| Natural Language Processing | 1 | 2017 | 69 | 0.040 |
Why?
|
| Sex Chromosome Aberrations | 1 | 2016 | 6 | 0.040 |
Why?
|
| Receptors, N-Methyl-D-Aspartate | 1 | 2019 | 266 | 0.040 |
Why?
|
| Chromosomes, Human, X | 1 | 2016 | 24 | 0.040 |
Why?
|
| Gene Dosage | 1 | 2016 | 47 | 0.040 |
Why?
|
| Trisomy | 1 | 2016 | 47 | 0.030 |
Why?
|
| Genotyping Techniques | 1 | 2016 | 19 | 0.030 |
Why?
|
| Vitamin D-Binding Protein | 1 | 2016 | 58 | 0.030 |
Why?
|
| In Situ Hybridization, Fluorescence | 1 | 2016 | 144 | 0.030 |
Why?
|
| Machine Learning | 1 | 2017 | 170 | 0.030 |
Why?
|
| Sarcoidosis | 1 | 2016 | 77 | 0.030 |
Why?
|
| Sex Distribution | 1 | 2016 | 272 | 0.030 |
Why?
|
| Health Care Costs | 1 | 2018 | 346 | 0.030 |
Why?
|
| Microarray Analysis | 1 | 2015 | 63 | 0.030 |
Why?
|
| Real-Time Polymerase Chain Reaction | 1 | 2016 | 209 | 0.030 |
Why?
|
| Practice Patterns, Physicians' | 1 | 2019 | 503 | 0.030 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2018 | 929 | 0.030 |
Why?
|
| Receptors, Complement 3b | 1 | 2014 | 35 | 0.030 |
Why?
|
| Drug Administration Schedule | 1 | 2015 | 567 | 0.030 |
Why?
|
| Reactive Oxygen Species | 1 | 2017 | 499 | 0.030 |
Why?
|
| Electrophoretic Mobility Shift Assay | 1 | 2014 | 60 | 0.030 |
Why?
|
| Chromosomes, Human, Pair 8 | 1 | 2014 | 54 | 0.030 |
Why?
|
| Tension-Type Headache | 1 | 2013 | 1 | 0.030 |
Why?
|
| Cluster Headache | 1 | 2013 | 3 | 0.030 |
Why?
|
| Granulocyte-Macrophage Colony-Stimulating Factor | 1 | 2014 | 101 | 0.030 |
Why?
|
| Patient Safety | 1 | 2015 | 202 | 0.030 |
Why?
|
| Telomere Homeostasis | 1 | 2013 | 6 | 0.030 |
Why?
|
| NADH Dehydrogenase | 1 | 2013 | 13 | 0.030 |
Why?
|
| Glutathione Reductase | 1 | 2013 | 17 | 0.030 |
Why?
|
| Genetic Variation | 1 | 2014 | 220 | 0.030 |
Why?
|
| Electron Transport Complex I | 1 | 2013 | 20 | 0.030 |
Why?
|
| Nitric Oxide Synthase Type I | 1 | 2013 | 35 | 0.030 |
Why?
|
| Azathioprine | 1 | 2013 | 16 | 0.030 |
Why?
|
| Intracranial Hypertension | 1 | 2013 | 53 | 0.030 |
Why?
|
| 3' Untranslated Regions | 1 | 2013 | 56 | 0.030 |
Why?
|
| Immunodiffusion | 1 | 2012 | 19 | 0.030 |
Why?
|
| Seroepidemiologic Studies | 1 | 2012 | 41 | 0.030 |
Why?
|
| Estrogens | 1 | 2014 | 173 | 0.030 |
Why?
|
| Migraine Disorders | 1 | 2013 | 66 | 0.030 |
Why?
|
| Cell Line, Transformed | 1 | 2012 | 100 | 0.030 |
Why?
|
| Mycophenolic Acid | 1 | 2013 | 62 | 0.030 |
Why?
|
| Dose-Response Relationship, Immunologic | 1 | 2012 | 31 | 0.030 |
Why?
|
| Survival Rate | 1 | 2015 | 1055 | 0.030 |
Why?
|
| Methotrexate | 1 | 2013 | 91 | 0.030 |
Why?
|
| Genetics, Population | 1 | 2012 | 21 | 0.030 |
Why?
|
| Canada | 1 | 2013 | 266 | 0.030 |
Why?
|
| Career Mobility | 1 | 2012 | 34 | 0.030 |
Why?
|
| Intercellular Adhesion Molecule-1 | 1 | 2012 | 52 | 0.030 |
Why?
|
| Silicon Dioxide | 1 | 2012 | 61 | 0.030 |
Why?
|
| Sierra Leone | 1 | 2011 | 5 | 0.030 |
Why?
|
| Congresses as Topic | 1 | 2012 | 85 | 0.030 |
Why?
|
| Mentors | 1 | 2012 | 81 | 0.030 |
Why?
|
| Social Problems | 1 | 2011 | 13 | 0.030 |
Why?
|
| Aged, 80 and over | 2 | 2014 | 4843 | 0.030 |
Why?
|
| Intracranial Thrombosis | 1 | 2011 | 14 | 0.030 |
Why?
|
| Solvents | 1 | 2012 | 108 | 0.030 |
Why?
|
| Emigration and Immigration | 1 | 2011 | 33 | 0.030 |
Why?
|
| Lupus Erythematosus, Discoid | 1 | 2011 | 6 | 0.030 |
Why?
|
| Career Choice | 1 | 2012 | 98 | 0.030 |
Why?
|
| Chromosomes, Human, Pair 1 | 1 | 2011 | 28 | 0.030 |
Why?
|
| Oral Ulcer | 1 | 2011 | 22 | 0.030 |
Why?
|
| Chronic Disease | 1 | 2016 | 1329 | 0.030 |
Why?
|
| Sequence Analysis, DNA | 1 | 2012 | 208 | 0.030 |
Why?
|
| Georgia | 1 | 2011 | 161 | 0.030 |
Why?
|
| Tumor Necrosis Factor alpha-Induced Protein 3 | 1 | 2011 | 7 | 0.030 |
Why?
|
| Ovarian Neoplasms | 1 | 2013 | 267 | 0.020 |
Why?
|
| Environment | 1 | 2011 | 115 | 0.020 |
Why?
|
| Oklahoma | 1 | 2010 | 18 | 0.020 |
Why?
|
| Lipoprotein(a) | 1 | 2010 | 9 | 0.020 |
Why?
|
| Placebos | 1 | 2010 | 195 | 0.020 |
Why?
|
| Gene Deletion | 1 | 2011 | 235 | 0.020 |
Why?
|
| Neoplasm Proteins | 1 | 2012 | 307 | 0.020 |
Why?
|
| Nerve Tissue Proteins | 1 | 2012 | 290 | 0.020 |
Why?
|
| Transcription Factors | 1 | 2014 | 753 | 0.020 |
Why?
|
| Triglycerides | 1 | 2010 | 184 | 0.020 |
Why?
|
| C-Reactive Protein | 1 | 2010 | 180 | 0.020 |
Why?
|
| Hypertension | 1 | 2019 | 1531 | 0.020 |
Why?
|
| Base Sequence | 1 | 2011 | 1015 | 0.020 |
Why?
|
| Absorptiometry, Photon | 1 | 2009 | 83 | 0.020 |
Why?
|
| Cholesterol | 1 | 2010 | 331 | 0.020 |
Why?
|
| Mice, Knockout | 1 | 2013 | 1692 | 0.020 |
Why?
|
| Acute Disease | 1 | 2010 | 658 | 0.020 |
Why?
|
| GTP-Binding Proteins | 1 | 2010 | 231 | 0.020 |
Why?
|
| Transfection | 1 | 2010 | 782 | 0.020 |
Why?
|
| Molecular Sequence Data | 1 | 2011 | 1446 | 0.020 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2010 | 710 | 0.020 |
Why?
|
| Lipoproteins, LDL | 1 | 2010 | 343 | 0.020 |
Why?
|
| Citrulline | 1 | 2006 | 9 | 0.020 |
Why?
|
| Cathelicidins | 1 | 2006 | 11 | 0.020 |
Why?
|
| Steroid Hydroxylases | 1 | 2006 | 19 | 0.020 |
Why?
|
| Random Allocation | 1 | 2007 | 442 | 0.020 |
Why?
|
| Hospital Mortality | 1 | 2008 | 384 | 0.020 |
Why?
|
| Colony Count, Microbial | 1 | 2006 | 77 | 0.020 |
Why?
|
| Mutation | 1 | 2011 | 1213 | 0.020 |
Why?
|
| Tuberculosis | 1 | 2006 | 77 | 0.020 |
Why?
|
| Disease Susceptibility | 1 | 2006 | 179 | 0.020 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 1 | 2006 | 320 | 0.020 |
Why?
|
| Cells, Cultured | 1 | 2010 | 2673 | 0.020 |
Why?
|
| Peptides | 1 | 2006 | 455 | 0.010 |
Why?
|
| Breast Neoplasms | 1 | 2013 | 1533 | 0.010 |
Why?
|